版本:
中国

BRIEF-Atossa Genetics qtrly loss per basic common share $0.45

May 11 Atossa Genetics Inc:

* Qtrly loss per basic common share $0.45

* "we are in the research and development phase and do not generate revenue"

* Plans to commence a phase 2 clinical study of endoxifen in second half of 2017 Source text (bit.ly/2qYPv5E) Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐